REEBX
Price
$55.67
Change
-$0.00 (-0.00%)
Updated
Sep 6 closing price
RERCX
Price
$55.09
Change
-$0.00 (-0.00%)
Updated
Sep 6 closing price
Ad is loading...

REEBX vs RERCX

Header iconREEBX vs RERCX Comparison
Open Charts REEBX vs RERCXBanner chart's image
American Funds Europacific Growth R2E
Price$55.67
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
American Funds Europacific Growth R3
Price$55.09
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
REEBX vs RERCX Comparison Chart
Loading...
VS
REEBX vs. RERCX commentary
Sep 16, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is REEBX is a Buy and RERCX is a Buy.

FUNDAMENTALS
Fundamentals
REEBX (136B) and RERCX (136B) have equal amount of cash in the bank . RERCX pays higher dividends than REEBX: RERCX (1.29) vs REEBX (1.16). REEBX was incepted earlier than RERCX: REEBX (10 years) vs RERCX (22 years). REEBX (34.00) and RERCX (34.00) have comparable annual turnover. REEBX (250) and RERCX (250) have matching initial minimum investment requirements. RERCX (10.94) and REEBX (10.80) have marching annual gain over last year. RERCX (13.06) and REEBX (12.54) have equivalent 5 years return.
REEBXRERCXREEBX / RERCX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence10 years22 years-
Gain YTD6.6796.79398%
Front LoadN/AN/A-
Min. Initial Investment250250100%
Min. Initial Investment IRAN/AN/A-
Net Assets136B136B100%
Annual Yield % from dividends1.161.2990%
Returns for 1 year10.8010.9499%
Returns for 3 years-17.73-17.50101%
Returns for 5 years12.5413.0696%
Returns for 10 years20.1421.1695%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RMBL4.260.19
+4.67%
RumbleOn
ACLS103.273.68
+3.70%
Axcelis Technologies
BRCC3.310.06
+1.85%
BRC
FNV125.130.12
+0.10%
Franco-Nevada Corp
MYNZ0.30-0.02
-4.87%
Mainz Biomed NV